¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary antibody deficiency"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary amenorrhea
    ¼Ó¹ß¹«¿ù°æ
  • secondary aqueous
    Àç»ý¹æ¼ö, ÀÌÂ÷¹æ¼ö
  • secondary attack rate
    ÀÌÂ÷¹ßº´·ü
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • secondary cardiomyopathy
    ÀÌÂ÷½ÉÀå±ÙÀ°º´(Áõ), ÀÌÂ÷½É±Ùº´(Áõ)
  • secondary constriction
    ÀÌÂ÷ÇùÂø
  • secondary culture
    ÀÌÂ÷¹è¾ç
  • secondary dentin
    ÀÌÂ÷»ó¾ÆÁú
  • secondary dentition
    ÀÌÂ÷Ä¡¾Æ
  • secondary disease
    ¼Ó¹ßº´, ¼Ó¹ßÁúȯ
  • secondary dysmenorrhea
    ¼Ó¹ß¿ù°æÅë
  • secondary ending
    ÀÌÂ÷Á¾¸»
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary gout
    ÀÌÂ÷Åëdz
  • secondary hemorrhage
    ¼Ó¹ßÃâÇ÷, ÀÌÂ÷ÃâÇ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
  • antisperm antibody
    Ç×Á¤ÀÚÇ×ü
  • atypical antibody
    ºñÁ¤ÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
  • blocking antibody
    Â÷´ÜÇ×ü
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary culture
    µÎ¹øÂ°½É±â
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • deficiency
    °áÇÌ(Áõ)
  • deficiency disease
    ¿µ¾ç°áÇ̺´
  • fat deficiency disease
    Áö¹æ°áÇÌÁõ
  • functional deficiency
    ±â´É°áÇÌ
  • histogenetic deficiency
    Á¶Á÷¹ß»ý°áÇÌ
  • immune deficiency
    (¢¡immunodeficiency) ¸é¿ª°áÇÌ
  • latent deficiency
    ÀáÀç°áÇÌÁõ
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌÁõ
  • mental deficiency
    Á¤½Å¹Ú¾à
  • milk dietary deficiency
    ¿ìÀ¯¿µ¾çÀå¾Ö
  • mineral deficiency
    ¹«±âÁú°áÇÌ(Áõ)
  • nutritional deficiency disease
    ¿µ¾ç°áÇ̺´
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired immune deficiency
    ÈÄõ¼º ¸é¿ª°áÇÌ
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõ Øóæ¹ÌÀù¹ñøý¦ÏØ)
  • adenosine,deficiency
    °áÇÌÁõ(ÌÀù¹ñø)
  • adrenocortical deficiency
    ºÎ½ÅÇÇÁú°áÇÌÁõ.
  • aids=£¾acquired immune deficiency syndrome
    ÈÄõ¼º¸é¿ª°áÇÌÁõÈıº(ý­ô¸àõØóæ¹ÌÀù¹ñøý¦ÏØ)
  • alimentary deficiency =dietary d.
    ½Ä»çºÎÁ·, ¿µ¾çºÎÁ·.
  • anemia iron deficiency
    ö°áÇ̼º ºóÇ÷.
  • anemia,folate deficiency
    ¿±»ê°áÇÌ(ç¨ß«ÌÀù¹)
  • anterior pituitary deficiency
    ³úÇϼöüÀü¿±±â´ÉºÎÀü(Áõ)
  • anterior pituitary deficiency
    ÇϼöüÀü¿±±â´ÉºÎÀü(Áõ).
  • antitrypsin deficiency
    Çׯ®¸³½Å°áÇÌ
  • apolipoprotein C-Il deficiency
    ¾ÆÆ÷Áö´Ü¹é C-II °áÇÌ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anterior pituitary deficiency
    ÇϼöüÀü¿±±â´ÉºÎÀü(Áõ).
  • antitrypsin deficiency
    Çׯ®¸³½Å°áÇÌ
  • apolipoprotein C-Il deficiency
    ¾ÆÆ÷Áö´Ü¹é C-II °áÇÌ
  • apolipoprotein b, deficiency
    ¾ÆÆ÷¸®Æ÷´Ü¹éB°áÇÌÁõ(¡­Ó±ÛÜ¡­ÌÀù¹ñø)
  • arylsulfatase a deficiency
    ¾Æ¸±¼³ÆÄŸÁ¦ A °áÇÌÁõ(¡­ÌÀù¹ñø)
  • aspartylglycosamine amide hydrolase, deficiency
    Aspartylglycosamine amide hydrolase°áÇÌ(¡­ÌÀù¹)
  • biotin-deficiency
    ¹ÙÀÌ¿Àƾ°áÇÌÁõ (¡­ÌÀù¹ñø).
  • biotin-deficiency
    ¹ÙÀÌ¿Àƾ°áÇÌÁõ (¡­ÌÀù¹ñø)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(Áõ)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(¡­ý£áÈÌÀù¹).
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • c3 deficiency
    C3 °áÇÌÁõ (¡­ÌÀù¹ñø)
  • carnitine palmitoyl transferase, deficiency
    Carnitine palmitoyl transferase, deficiency
  • cell adhesion molecular deficiency
    ¼¼Æ÷À¯ÂøºÐÀÚ°áÇÌ
  • cell deficiency (aganglionic megacolon)
    ¼¼Æ÷ÀÌÁÖ°áÇÌ (¹«½Å°æÀýÁÖ¸§Ã¢ÀÚ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Secretion deficiency
    ºÐºñ°áÇÌ
    [¿¾ ¿ë¾î] ºÐºñ°áÇÌ
  • Cytogenetic deficiency
    ¼¼Æ÷¹ß»ý°áÇÌ
    [¿¾ ¿ë¾î] ¼¼Æ÷¹ß»ý°áÇÌ
  • Stimulus deficiency
    ÀڱذáÇÌ
    [¿¾ ¿ë¾î] ÀڱذáÇÌ
  • Histogenetic deficiency
    Á¶Á÷¹ß»ý°áÇÌ
    [¿¾ ¿ë¾î] Á¶Á÷¹ß»ý°áÇÌ
  • Synthesis deficiency
    ÇÕ¼º°áÇÌ
    [¿¾ ¿ë¾î] ÇÕ¼º°áÇÌ
  • Hormone deficiency
    È£¸£¸ó°áÇÌ
    [¿¾ ¿ë¾î] È£¸£¸ó°áÇÌ
  • Secondary segmental bronchus
    ±¸¿ª±â°üÁö°¡Áö
    [¿¾ ¿ë¾î] ÀÌÂ÷±¸±â°üÁö
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
  • Secondary spiral lamina
    µÑ°³ª¼±ÆÇ
    [¿¾ ¿ë¾î] Á¦2³ª¼±ÆÇ
  • Secondary fissure
    µÑ°ƴ»õ
    [¿¾ ¿ë¾î] Á¦2¿­
  • Secondary polar body
    ÀÌÂ÷±ØÃ¼
    [¿¾ ¿ë¾î] ÀÌÂ÷±ØÃ¼
  • Secondary oocyte
    ÀÌÂ÷³­¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­¸ð¼¼Æ÷
  • Secondary oocyte, Metaphase II
    ÀÌÂ÷³­¸ð¼¼Æ÷, ÀÌÂ÷°¨¼öºÐ¿­Áß±â
    [¿¾ ¿ë¾î] Á¦À̳­¸ð¼¼Æ÷,ÀÌÂ÷Áß±â
  • Secondary follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary ovarian follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
  • secondary bond
    ÀÌÂ÷ °áÇÕ(ì£ó­Ì¿ùê)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary culture
    ÀÌÂ÷ ¹è¾ç(ì£ó­ÛÆå×)
  • secondary derived protein
    ÀÌÂ÷ À¯µµ´Ü¹éÁú(ì£ó­ë¯ÓôÓ±ÛÜòõ)
  • secondary electron
    ÀÌÂ÷ ÀüÀÚ(ì£ó­ï³í­)
  • secondary fluor
    ÀÌÂ÷ Çü±¤Á¦(ì£ó­û«ÎÃð¥)
  • secondary hydration shell
    ÀÌÂ÷(ì£ó­) ¼öÈ­ â©ûù ²®Áú
  • secondary ionization
    ÀÌÂ÷(ì£ó­) ÀÌ¿ÂÈ­(ûù)
  • secondary ion mass spectrometry
    ÀÌÂ÷ ÀÌ¿ÂÁú·®ºÐ±¤¹ý(ì£ó­òõÕáÝÂÎÃÛö)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • secondary lysosome
    ÀÌÂ÷(ì£ó­) ¶óÀ̼ҼØ
  • secondary malnutrition
    ÀÌÂ÷ ¿µ¾ç½ÇÁ¶(ì£ó­ç½å×ã÷ðà)
  • secondary messenger
    ÀÌÂ÷ Àü·É (ì£ó­îîÖµ)
  • secondary metabolite
    ÀÌÂ÷ ´ë»ç¹°(ì£ó­ÓÛÞóÚª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary sex characteristic
    ÀÌÂ÷¼ºÂ¡
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
  • secondary tuberculosis
    ÀÌÂ÷¼º°áÇÙ
  • secondary X-ray
    ÀÌÂ÷X¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IGD idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency
MCD magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ...
ADS acute death syndrome; acute diarrheal syndrome; Alcohol Dependence Scale; alternative delivery syste...
HI antibody Hemagglutination Inhibiting antibody; Ç÷±¸ ÀÀÁý ¾ïÁ¦ Ç×ü
AHA acetohydroxamic acid; acquired hemolytic anemia; acute hemolytic anemia; American Heart Association;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SIMS Secondary ion mass spectroscopy
SP Secondary progressive
ToF-SIMS Time of Flight Secondary Ion Mass Spectrometry
SE secondary electron
SHPT secondary hyperparathyroidism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • secondary herpes simplex
    ÀÌÂ÷Àû ±¸¼ø Æ÷Áø
  • secondary hyperalgesia
    ¼Ó¹ß¼º Åë°¢ °ú¹Î, ÀÌÂ÷Àû Åë°¢ °ú¹Î
    µ¿ÀǾî=secondary hy
  • secondary hyperparathyroidism
    ¼Ó¹ß¼º ºÎ°©»ó¼± ±â´É Ç×Áø, ¼Ó¹ß¼º ºÎ°©»ó¼± ±â´É Ç×ÁøÁõ
  • secondary hypertrophic osteoarthropathy
    ¼Ó¹ß¼º ºñ´ë¼º °ñ °üÀýº´Áõ
  • secondary impression
    ÀÌÂ÷ Àλó
  • secondary inoculation
    ÀÌÂ÷ Á¢Á¾
  • secondary lesion
    ÀÌÂ÷¼º º´º¯, ÀÌÂ÷ ¹ßÁø, ¼Ó¹ßÁø
  • secondary local muscle soreness
    ¼Ó¹ß¼º ±¹¼Ò ±Ùµ¿Åë
  • secondary occlusal trauma
    ¼Ó¹ß¼º ±³ÇÕ ¿Ü»ó
    ÀÌ¹Ì Ä¡ÁÖ ÁúȯÀÌ ÀÖ´Â Ä¡¾Æ¿¡ °¡ÇØÁø °úµµÇÑ ±³ÇÕ·ÂÀ¸·Î ÀÎÇÑ Ä¡ÁÖ Á¶Á÷ÀÇ ¿Ü»ó.
  • secondary ossification center
    ÀÌÂ÷ °ñÈ­ Áß½É
  • secondary osteon
    ÀÌÂ÷ »À ´ÜÀ§
  • secondary pain
    ¼Ó¹ß¼º ÅëÁõ, Á¦ÀÌ µ¿Åë
    µ¿ÀǾî=referred
  • secondary palate
    ÀÌÂ÷ ±¸°³
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antibody diversity The phenomenon of immense variability characteristic of antibodies, which enables the immune system to react specifically against the essentially unlimited kinds of antigens it encounters. Antibody diversity is accounted for by three main theories: 1) the germ line theory, which holds that each antibody-producing cell has genes coding for all possible antibody specificities, but expresses only the one stimulated by antigen; 2) the somatic mutation theory, which holds that antibody-producing cells contain only a few genes, which produce antibody diversity by mutation; and 3) the gene rearrangement theory, which holds that antibody diversity is generated by the rearrangement of variable region gene segments during the differentiation of the antibody-producing cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • secondary industry
    Á¦ 2Â÷ »ê¾÷
  • secondary school
    Áßµî Çб³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á